CA3149482A1 — Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
Assigned to Mersana Therapeutics Inc · Expires 2021-02-11 · 5y expired
What this patent protects
The present disclosure relates to compounds of formula (IA') as STING (Stimulator of Interferon Genes) agonists for use in the treatment of e.g. cancer, obesity, liver injuries, sugar-lipid metabolism and virus infections. The present description discloses the synthesis and chara…
USPTO Abstract
The present disclosure relates to compounds of formula (IA') as STING (Stimulator of Interferon Genes) agonists for use in the treatment of e.g. cancer, obesity, liver injuries, sugar-lipid metabolism and virus infections. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 128 to 286; examples 1 to 54; tables 1, 2a, 2b and 3). An exemplary compounds is e.g. example 1: (E)-N-(5-carbamoyl- l-(4-(5-carbamoyl-2-(4-ethyl-2-methyloxazole-5-carboxamido)-7- (3-hydroxypropoxy)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-7- methoxy-1H-benzo[d]imidazol-2-yl)-4-ethyl-2-methyloxazote-5- carboxamide (compound 9).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.